DEF: BioVie Seeks Shareholder Approval for Equity Plan Expansion

BioVie Inc. will hold its 2025 Annual Meeting virtually to elect directors, ratify auditors, and approve a significant increase in shares for its equity incentive plan.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Monday, November 10, 2025, at 11:00 a.m. Pacific Time.
• Stockholders will vote on the election of six directors, the ratification of EisnerAmper LLP as the independent registered public accounting firm for fiscal year ending June 30, 2026, and an amendment to the 2019 Omnibus Equity Incentive Plan.
• The proposed amendment to the 2019 Omnibus Equity Incentive Plan seeks to increase the number of shares authorized for issuance to 3,100,000.
• As of September 22, 2025, there were 7,535,080 shares of common stock outstanding and entitled to vote.
• The company reported a net loss of $(17,912) thousand for fiscal year 2025, an improvement from $(33,007) thousand in fiscal year 2024.
• The value of an initial $100 investment based on total shareholder return decreased significantly from $9.30 in 2024 to $2.15 in 2025.
• Audit fees for EisnerAmper LLP increased from $244,425 in 2024 to $343,075 in 2025, with additional audit-related and tax fees totaling $126,000 in 2025.

Sentiment

Score: 4

Explanation: The filing presents a mixed picture. While the reduction in net loss is positive, the significant decline in total shareholder return and the numerous delinquent Section 16(a) reports are concerning. The proposed equity plan expansion, while necessary for talent retention, carries a substantial dilution risk for existing shareholders. The overall sentiment is cautious due to poor stock performance and governance issues, despite some operational improvements.

Positives

• Net loss improved from $(33,007) thousand in fiscal year 2024 to $(17,912) thousand in fiscal year 2025, indicating a reduction in losses.
• The Board of Directors unanimously recommends voting for all proposals, including the election of director nominees and the equity incentive plan expansion, suggesting internal confidence.
• The company continues to attract and retain experienced professionals on its board and in executive roles, with new directors like Dr. Amy Chappell and Mr. Kameel Farag bringing significant industry and financial expertise.

Negatives

• The total shareholder return for an initial $100 investment significantly declined from $9.30 in 2024 to $2.15 in 2025, indicating poor stock performance.
• Several executive officers and directors had delinquent Section 16(a) reports for fiscal year 2025, raising concerns about timely regulatory compliance.
• The proposed increase in authorized shares for the equity incentive plan to 3,100,000 could lead to significant shareholder dilution, as it represents a substantial portion of the outstanding shares (approximately 20% on a fully diluted basis).

Risks

• Potential shareholder dilution from the proposed increase of shares authorized for the 2019 Omnibus Equity Incentive Plan to 3,100,000 shares.
• Regulatory compliance risk due to delinquent Section 16(a) reports filed by multiple executive officers and directors for fiscal year 2025.
• The company's stock performance, as indicated by the decline in the value of a $100 investment from $9.30 in 2024 to $2.15 in 2025, suggests ongoing market challenges or operational concerns.

Future Outlook

The company aims to continue attracting, retaining, and motivating key management, non-employee directors, and consultants by expanding its equity compensation plan. If approved, the 2019 Plan is expected to have sufficient shares for awards until approximately 2026, supporting future talent acquisition and retention strategies.

Management Comments

• The Board of Directors recommends that you vote FOR each of the director nominees and FOR each of the other proposals outlined in the accompanying Proxy Statement.
• The Board believes that our interests and the interests of our stockholders will be advanced if we can continue to offer our key management employees, non-employee directors and consultants the opportunity to acquire or increase their proprietary interests in the Company.
• The Board has concluded that our ability to attract, retain and motivate top quality management would be enhanced by our continued ability to grant equity compensation under the 2019 Plan.

Industry Context

The expansion of BioVie's equity incentive plan is a common strategy in the biotechnology and pharmaceutical industries to attract and retain highly skilled talent, given the long development cycles and high-risk nature of drug development. Competitive equity compensation is crucial for companies like BioVie to align employee incentives with long-term shareholder value, especially when cash compensation might be constrained during R&D phases. The virtual annual meeting format is also a continuing trend, reflecting modern corporate governance practices.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• No related party transactions exceeding $120,000 or 1% of average total assets were reported since July 1, 2024.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution if the equity incentive plan amendment is approved, as it authorizes a large number of new shares. Poor total shareholder return in 2025 indicates negative impact on existing shareholder value. Voting rights are exercised at the annual meeting.
• **Employees & Directors:** The expanded equity incentive plan is designed to attract, retain, and motivate key personnel by offering proprietary interests in the company, potentially increasing their long-term compensation and alignment with company success.
• **Regulatory Bodies:** Delinquent Section 16(a) reports by multiple insiders could draw scrutiny from the SEC regarding compliance and corporate governance.

Next Steps

• Stockholders to vote on director elections, auditor ratification, and the 2019 Omnibus Equity Incentive Plan amendment at the Annual Meeting on November 10, 2025.
• Final voting results will be reported in a Current Report on Form 8-K within four business days of the Annual Meeting.
• Stockholders interested in submitting proposals or nominations for the 2026 Annual Meeting must do so between August 12, 2026, and October 11, 2026.

Key Dates

Recommendation

The filing presents a mixed bag. While the company showed an improvement in reducing its net loss, the significant decline in total shareholder return for 2025 is a major concern, indicating poor stock performance. The proposed expansion of the equity incentive plan, while crucial for talent retention in the biotech sector, carries a substantial dilution risk for existing shareholders. Furthermore, the numerous delinquent Section 16(a) reports by insiders raise questions about internal controls and regulatory compliance. Given the improved net loss but severe underperformance in shareholder return and governance issues, a 'hold' recommendation is appropriate. Investors should monitor future financial results, the impact of the equity plan, and improvements in regulatory compliance before considering further investment.

Keywords

Biotech, Pharmaceutical, SEC Filing, Proxy Statement, Corporate Governance, Equity Incentive Plan, Stock Options, Restricted Stock Units, Shareholder Meeting, Director Election, Auditor Ratification, Executive Compensation, Financial Reporting, Risk Management